• Company
• Hanmi Pharm ‘confirms the effect of SERM+Vitamin D combo’
• by Son, Hyung-Min Feb 29, 2024 06:03am

• Product
• NA Opp party in unison say ‘it's time for INN prescribing'
• by Kim JiEun Feb 29, 2024 06:03am

• Company
• Roche Korea appoints Ezat Azem as new CEO
• by Eo, Yun-Ho Feb 29, 2024 06:03am

• Company
• K-Bio’s potential rises in targeted anticancer therapy
• by Son, Hyung-Min Feb 29, 2024 06:03am

• Company
• Saxenda and Qsymia take up 57% of the obesity market share
• by Chon, Seung-Hyun Feb 28, 2024 10:35am

• Company
• KRPIA appoints Sanofi CEO Kay Bae as new chair
• by Feb 28, 2024 05:50am

• Policy
• Patients bear 100% of Imfinzi cost for biliary tract cancer
• by Lee, Tak-Sun Feb 28, 2024 05:50am

• Company
• Immuno-oncology market triples in 4 years
• by Son, Hyung-Min Feb 28, 2024 05:50am

• Company
• Will the first oHCM drug Camzyos be reimbursed in Korea?
• by Eo, Yun-Ho Feb 28, 2024 05:50am

• Company
• Samsung Bioepis confirms efficacy of its Eylea biosimilar
• by Nho, Byung Chul Feb 27, 2024 05:45am